https://www.selleckchem.com/products/BEZ235.html
0%, 1.6% (p = .04 and 0.6% (p less then .001), respectively. Moreover, patients in the Group B exhibited better virologic response (100% vs. 98.8%, p less then .001) and HBeAg seroconversion (92.6% vs. 69.8%, p less then .001) than those in Group D at year 5. Propensity score-matched analysis also showed the similar trend of HBsAg decline. NAs discontinuation with or without subsequent retreatment resulted in a more profound reduction of HBsAg in non-cirrhotic HBeAg-positive patients, suggesting that discontinuation may be a potential
Like
Comment
Share
